Efficacy of Aspirin Therapy After Desensitization on Chronic Rhinosinusitis With Nasal Polyps Patients With Asthma and Non‐steroidal Anti‐inflammatory Drug Exacerbated Respiratory Disease —A Randomized Clinical Trial
Allergy · 2025
DOI: 10.1111/all.16679 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Allergy, 2025. Verfasst von Alma Helevä und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergology, Inflammation Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. Hauptthemen laut MEDLINE: Nasal Polyps, Sinusitis, Aspirin, Desensitization, Immunologic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Jalmari ja Rauha Ahokkaan Säätiö, State funding for university-level health research, Investigator-Sponsored Study of Sanofi.
Abstract (Originalsprache)
Non‐steroidal anti‐inflammatory drug (NSAID) exacerbated respiratory disease (N‐ERD) is a chronic inflammatory condition typically involving hypersensitivity to NSAIDs, asthma, and/or chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP). N‐ERD increases the risk for severe hypersensitivity reactions, recurring sinonasal surgeries, or the need for systemic corticosteroid treatment. Aspirin (ASA) treatment after desensitization (ATAD) is a treatment option for N‐ERD. Desensitization to ASA is reached with increasing ASA doses over a few days, followed by a long‐term treatment. This study evaluated the efficacy of ATAD with an ASA dose of 250 mg in adult CRSwNP patients with asthma and N‐ERD. Forty‐one CRSwNP patients with comorbid asthma and N‐ERD were recruited for this randomized double‐blind clinical trial. Twenty‐six patients had successful ASA desensitization, were randomized into placebo and ASA arms, and continued to 11 months of daily ASA, with a target dose of 250 mg. The outcome measures, including Sino‐Nasal Outcome Test 22 (SNOT‐22), nasal polyp score (NPS), Asthma Control Test (ACT), and EPOS 2012 CRS clinical control assessment, were evaluated at control visits at 1, 5, 11, and 12 months after the start of the treatment. In the linear mixed effects model, p ‐values for the combined effect of group and time showed no difference between placebo and ATAD for SNOT‐22, ACT, and NPS, with p ‐values 0.17, 0.45, and 0.18, respectively. Neither group showed significant improvement in the EPOS 2012 CRS control assessment. In conclusion, no significant clinical difference was observed between ATAD and placebo in the treatment of CRSwNP patients with asthma and N‐ERD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Allergology, Inflammation Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
- MD PhD Programme of the Faculty of Medicine, University of Helsinki, Helsinki, Finland.
- Department of Otorhinolaryngology-Head and Neck Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
- Department of Otorhinolaryngology, University of Eastern Finland, Kuopio, Finland.
- Heart and Lung Center, Department of Pulmonary Diseases and Allergology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
- Department of Otorhinolaryngology, Kuopio University Hospital, Wellbeing Services County of North Savo, Kuopio, Finland.
ORCID-Profile: Alma Helevä, Annina Lyly, Viljami Salmi, Mika Mäkelä, Paula Kauppi, Anu Laulajainen-Hongisto, Lena Hafrén, Paula Virkkula, Mikko Nuutinen, Sanna Toppila-Salmi
Förderung
- Jalmari ja Rauha Ahokkaan Säätiö
- State funding for university-level health research
- Investigator-Sponsored Study of Sanofi
- The Finnish Society of Allergology and Immunology
- MD PhD Programme of the Faculty of Medicine, University of Helsinki
- Suomen Tuberkuloosin Vastustamisyhdistyksen Säätiö
- Allergiatutkimussäätiö
- Orionin Tutkimussäätiö
Zitieren
APA
Helevä, A., Lyly, A., Salmi, V., Mäkelä, M., Kauppi, P., Laulajainen-Hongisto, A., Hafrén, L., Virkkula, P., Nuutinen, M., & Toppila-Salmi, S. (2025). Efficacy of Aspirin Therapy After Desensitization on Chronic Rhinosinusitis With Nasal Polyps Patients With Asthma and Non‐steroidal Anti‐inflammatory Drug Exacerbated Respiratory Disease —A Randomized Clinical Trial. Allergy. https://doi.org/10.1111/all.16679
Vancouver
Helevä A, Lyly A, Salmi V, Mäkelä M, Kauppi P, Laulajainen-Hongisto A, et al. Efficacy of Aspirin Therapy After Desensitization on Chronic Rhinosinusitis With Nasal Polyps Patients With Asthma and Non‐steroidal Anti‐inflammatory Drug Exacerbated Respiratory Disease —A Randomized Clinical Trial. Allergy. 2025. doi:10.1111/all.16679
BibTeX
@article{Helev2025,
author = {Helevä, Alma and Lyly, Annina and Salmi, Viljami and Mäkelä, Mika and Kauppi, Paula and Laulajainen-Hongisto, Anu and Hafrén, Lena and Virkkula, Paula and Nuutinen, Mikko and Toppila-Salmi, Sanna},
title = {Efficacy of Aspirin Therapy After Desensitization on Chronic Rhinosinusitis With Nasal Polyps Patients With Asthma and Non‐steroidal Anti‐inflammatory Drug Exacerbated Respiratory Disease —A Randomized Clinical Trial},
journal = {Allergy},
year = {2025},
doi = {10.1111/all.16679}
}
EUVIMED